FdaApplication
NDA 210806
Identifiers
- fda_app_no: NDA210806
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2018-08-30 |
Revenue by product
PIFELTRO
| Period | Revenue |
|---|---|
| Q4 2025 | $43.0M |
| Q3 2025 | $43.0M |
| Q2 2025 | $41.0M |
| Q1 2025 | $45.0M |
| Q4 2024 | $40.0M |
| Q3 2024 | $42.0M |
| Q2 2024 | $39.0M |
| Q1 2024 | $42.0M |
| Q4 2023 | $33.0M |
| Q3 2023 | $37.0M |
| Q2 2023 | $38.0M |
| Q1 2023 | $34.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PIFELTRO | DORAVIRINE | 100MG | TABLET;ORAL |
1 product